A model of so called “BioNtainers”, a container-based production line of mRNA-based vaccines of German company BioNTech, is pictured at the company’s plant in Marburg, Germany, February 11, 2022. REUTERS/Fabian Bimmer/File Photo
A model of so called “BioNtainers”, a container-based production line of mRNA-based vaccines of German company BioNTech, is pictured at the company’s plant in Marburg, Germany, February 11, 2022. REUTERS/Fabian Bimmer/File Photo